A study looking at everolimus for neuroendocrine tumours of the pancreas (The OBLIQUE study)

This study is to find out more about the drug everolimus (also known Afinitor) as a treatment for neuroendocrine tumours of the pancreas.

Neuroendocrine tumours (NETs) are a rare group of cancers that make and release hormones. They are normally found in the digestive system. This trial is looking at neuroendocrine tumours of the pancreas.

Doctors may treat neuroendocrine tumours of the pancreas with a drug called everolimus. It is a type of biological therapy. It stops a protein called mTOR from working properly which can help to stop cancer growing.

We know that everolimus can help people who have pancreatic neuroendocrine tumours that can’t be removed with surgery, or have spread to another part of the body. In this study, researchers want to

• Learn more about how everolimus affects people’s quality of life

• See how well it works in the long term for pancreatic neuroendocrine tumours